AR111464A1 - Terapia combinada para el tratamiento de infecciones virales - Google Patents
Terapia combinada para el tratamiento de infecciones viralesInfo
- Publication number
- AR111464A1 AR111464A1 ARP180100933A ARP180100933A AR111464A1 AR 111464 A1 AR111464 A1 AR 111464A1 AR P180100933 A ARP180100933 A AR P180100933A AR P180100933 A ARP180100933 A AR P180100933A AR 111464 A1 AR111464 A1 AR 111464A1
- Authority
- AR
- Argentina
- Prior art keywords
- reverse transcriptase
- transcriptase inhibitor
- compound
- formula
- pharmaceutically acceptable
- Prior art date
Links
- 208000036142 Viral infection Diseases 0.000 title 1
- 238000002648 combination therapy Methods 0.000 title 1
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 abstract 6
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000003729 nucleotide group Chemical group 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 229940127073 nucleoside analogue Drugs 0.000 abstract 2
- 239000002777 nucleoside Substances 0.000 abstract 1
- 150000003833 nucleoside derivatives Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 230000010076 replication Effects 0.000 abstract 1
- 229960004556 tenofovir Drugs 0.000 abstract 1
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical group OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
- C07K7/645—Cyclosporins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente solicitud se relaciona con un método para tratar y/o prevenir una enfermedad causada por el HBV o enfermedad causada por el HIV o para modular la replicación del HBV o del HIV, que comprende la administración a un sujeto que lo requiere un compuesto de fórmula (1), o una sal farmacéuticamente aceptable del mismo, combinado con un análogo nucleosídico inhibidor de la transcriptasa reversa o un análogo nucleotídico inhibidor de la transcriptasa reversa. Compuesto. Uso. Kit. Composición farmacéutica. Producto. Reivindicación 44: El método de la reivindicación 45, caracterizado porque el inhibidor de la transcriptasa inversa análogo de nucleósido o el inhibidor de la transcriptasa inversa análogo de nucleótido es tenofovir de fórmula (2), o una sal aceptable farmacéuticamente o prodroga del mismo. Reivindicación 45: El método de la reivindicación 45, caracterizado porque el inhibidor de la transcriptasa inversa análogo de nucleósido o el inhibidor de la transcriptasa inversa análogo de nucleótido es un compuesto de fórmula (3), o una sal aceptable farmacéuticamente del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762485510P | 2017-04-14 | 2017-04-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR111464A1 true AR111464A1 (es) | 2019-07-17 |
Family
ID=62090086
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP180100933A AR111464A1 (es) | 2017-04-14 | 2018-04-13 | Terapia combinada para el tratamiento de infecciones virales |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20180296588A1 (es) |
| AR (1) | AR111464A1 (es) |
| TW (1) | TW201902507A (es) |
| WO (1) | WO2018191579A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SMT202300139T1 (it) * | 2018-11-26 | 2023-07-20 | Hepion Pharmaceuticals Inc | Formulazioni farmaceutiche di analoghi della ciclosporina |
| CN115427060A (zh) | 2020-02-19 | 2022-12-02 | 海必恩制药公司 | 环孢菌素类似物用于治疗纤维化的用途 |
| AU2021227230A1 (en) * | 2020-02-25 | 2022-09-08 | Hepion Pharmaceuticals, Inc. | Use of cyclosporine analogues for treating cancer |
| GB202007106D0 (en) * | 2020-05-14 | 2020-07-01 | Ucl Business Plc | Cyclosporine analogues |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4160452A (en) | 1977-04-07 | 1979-07-10 | Alza Corporation | Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| FR2757520B1 (fr) * | 1996-12-24 | 1999-01-29 | Rhone Poulenc Rorer Sa | Derive de cyclosporine, sa preparation et les compositions pharmaceutiques qui le contiennent |
| US8642577B2 (en) | 2005-04-08 | 2014-02-04 | Chimerix, Inc. | Compounds, compositions and methods for the treatment of poxvirus infections |
| CN101977610B (zh) | 2008-01-25 | 2012-05-16 | 奇默里克斯公司 | 治疗病毒感染的方法 |
| JP6144627B2 (ja) | 2010-12-15 | 2017-06-07 | コントラヴィア ファーマシューティカルズ、インク． | アミノ酸１および３で修飾されたシクロスポリン類似体分子 |
| CN118324867A (zh) * | 2016-05-17 | 2024-07-12 | 美国科技环球有限公司 | 新型环孢菌素衍生物及其用途 |
-
2018
- 2018-04-13 AR ARP180100933A patent/AR111464A1/es unknown
- 2018-04-13 WO PCT/US2018/027418 patent/WO2018191579A1/en not_active Ceased
- 2018-04-13 TW TW107112726A patent/TW201902507A/zh unknown
- 2018-04-13 US US15/952,271 patent/US20180296588A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20180296588A1 (en) | 2018-10-18 |
| TW201902507A (zh) | 2019-01-16 |
| WO2018191579A1 (en) | 2018-10-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP20069416A (es) | Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak | |
| SA519402405B1 (ar) | مركبات مثبط فيروس نقص المناعة البشري | |
| CO2022005128A2 (es) | Profármacos antivirales y formulaciones de los mismos | |
| CL2019003091A1 (es) | Terapia de combinación. | |
| CO2026005655A2 (es) | Inhibidor de pan-kras y uso del mismo en medicinas | |
| MX388757B (es) | Profármacos de éster alifático antivíricos de tenofovir. | |
| ECSP22076862A (es) | Compuestos antivirales y métodos para la administración de los mismos | |
| UY37998A (es) | Agentes antivirales contra la hepatitis b | |
| NI201900099A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| BR112017010551A2 (pt) | composto, métodos para ativação de guanilato ciclase solúvel, para tratamento de uma ou mais condições selecionadas a partir de uma doença em um paciente e para tratamento de uma doença ou condição, composição farmacêutica, uso de um composto, e, medicamento. | |
| ECSP19083621A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| ECSP19070413A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| ECSP19083640A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| UY38228A (es) | Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer | |
| MX381440B (es) | Composicion farmaceutica para tratar colitis ulcerativa. | |
| MX2019002121A (es) | Tratamiento conjunto para tratar el cancer de pancreas. | |
| UY39510A (es) | Compuestos macrocíclicos y métodos para usarlos | |
| HRP20230300T1 (hr) | Kombinacije imetelstata i venetoklaksa za liječenje akutne mijeloidne leukemije | |
| BR112021011368A2 (pt) | Cocristal de cetoprofeno, composições compreendendo o mesmo, processo para a sua produção e usos dos mesmos | |
| AR114418A1 (es) | Compuesto cíclico de metilactama y su utilización farmacéutica | |
| MX389088B (es) | Métodos para tratar el vhc. | |
| MY199746A (en) | Pyrrolopyrimidine derivatives useful as inhibitors of influenza virus replication | |
| SG11201811516QA (en) | Liver delivery-based antiviral precursor drug nucleoside cyclophosphate compound and use thereof | |
| MX2020008360A (es) | Forma cristalina de bictegravir sodico. | |
| CL2018002705A1 (es) | Glucono delta-lactona para el tratamiento de infecciones fúngicas vaginales |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |